EMERALD Subgroup Analyses Demonstrate Safety, Efficacy of Switching Certain Patients With HIV to Symtuza AJMC, 04 Sep 2019 New subgroup analyses from the phase 3 EMERALD trial are supporting the safety and efficacy of switching treatment-experienced…